Back to top
more

La Jolla Pharmaceutical Company (LJPC)

(Delayed Data from NSDQ)

$8.26 USD

8.26
455,799

+0.22 (2.74%)

Updated May 3, 2019 04:00 PM ET

After-Market: $8.27 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[LJPC]

Reports for Purchase

Showing records 1 - 20 ( 72 total )

Industry: Medical - Drugs

Record: 1

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for LJPC

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 2

02/23/2020

Company Report

Pages: 7

Termination of Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 3

02/12/2020

Industry Report

Pages: 13

2020 Roadmap of Key Events Across Our Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 4

01/09/2020

Company Report

Pages: 6

Giapreza 4Q19 and FY19 Sales Preannounced

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 5

11/26/2019

Company Report

Pages: 7

Mixed Results for LJPC-401; CEO Dr. Tidmarsh Departs; Downgrading to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 6

11/13/2019

Company Report

Pages: 8

3Q19 Results; LJPC-401 Topline Phase 2 Data Projected for This Quarter: Lowering PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 7

08/29/2019

Daily Note

Pages: 3

Giapreza Receives European Commission''s Approval

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 8

08/02/2019

Company Report

Pages: 8

2Q19 Results; MAA Decision Expected for Giapreza This Quarter Could Be a Stock Catalyst

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 9

07/23/2019

Daily Note

Pages: 3

FDA Grants Orphan Drug Designation for LJPC-0118 to Treat Malaria

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 10

06/28/2019

Daily Note

Pages: 3

Giapreza MAA Gets Positive CHMP Opinion

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 11

06/06/2019

Company Report

Pages: 8

Win for La Jolla Interim Phase 2 Data in Hereditary Hemochromatosis Looks Good

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 12

05/07/2019

Company Report

Pages: 8

1Q19 Results; Giapreza Sales Slightly Lower Than Expected, Operating Expense Cuts Lead to EPS Beat; Adj PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 13

04/24/2019

Daily Note

Pages: 3

La Jolla Announces FDA Breakthrough Therapy Designation for LJPC-0118 in Severe Malaria

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 14

03/05/2019

Company Report

Pages: 8

La Jolla Reports 4Q18 Results; Giapreza and Platform Updates; PT to $26 from $25

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 15

01/09/2019

Company Report

Pages: 8

La Jolla Pharmaceutical Announces Key Objectives for 2019; Revenue Guidance Well Below Our Expectations

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 16

10/25/2018

Company Report

Pages: 8

Giapreza U.S. Launch Progressing; Europe Launch Expected 2H19; Revising PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 17

09/07/2018

Company Report

Pages: 8

Global Investment Conference: La Jolla Takeaways; Giapreza, Pipeline Progress

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 18

08/09/2018

Company Report

Pages: 6

La Jolla Pharma 2Q18 Results; Giapreza on Formularies of Over 200 Hospitals

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 19

07/27/2018

Company Report

Pages: 7

Updating Estimates; Lowering Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 20

05/11/2018

Company Report

Pages: 7

1Q18 Results: $125M Royalty Financing Agreement Announced; Price Target Lowered to $72 From $83

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party
// eof